High white blood cell count and low estimated glomerular filtration rate are independently associated with serum level of monocyte chemoattractant protein-1 in a general population

Clinical Cardiology

Volumn 34, Issue 3, 2011, Pages 189-194

  Fukami, Ako ^a   Yamagishi, Sho Ichi ^a   Adachi, Hisashi ^a   Matsui, Takanori ^a   Yoshikawa, Kuniko ^a   Ogata, Kinuka ^a   Kasahara, Akiko ^a   Tsukagawa, Eri ^a   Yokoi, Kanako ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; NITROGEN; UREA; URIC ACID;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD CHEMISTRY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; JAPANESE; KIDNEY FUNCTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

AGE FACTORS; AGED; ATHEROSCLEROSIS; CHEMOKINE CCL2; EPIDEMIOLOGIC STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; LEUKOCYTE COUNT; MALE; MIDDLE AGED; SEX FACTORS; STATISTICS AS TOPIC;

EID: 79952716296     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20834     Document Type: Article

References (37)

1. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J. 1992;6:2591-2599.
2. Yamagishi S, Matsui T, Nakamura K. Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders. Curr Pharm Des. 2009;15:1027-1033.
3. Vanden Berghe W, Vermeulen L, De Wilde G, et al. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol. 2000;60:1185-1195.
4. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986;163:740-745. (Pubitemid 16141974)
5. Mackay F, Loetscher H, Stueber D, et al. Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med. 1993;177:1277-1286. (Pubitemid 23117119)
6. Rollins BJ, Yoshimura T, Leonard EJ, et al. Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol. 1990;136:1229-1233. (Pubitemid 20210321)
7. Nelken NA, Coughlin SR, Gordon D, et al. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991;88:1121-1127.
8. Boring L, Gosling J, Cleary M, et al. Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-897. (Pubitemid 28410911)
9. De Lemos JA, Morrow DA, Blazing MA, et al. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol. 2007;50:2117-2124.
10. Piemonti L, Calori G, Lattuada G, et al. Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care. 2009;32:2105-2110.
11. Deo R, Khera A, McGuire DK, et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol. 2004;44:1812-1818. (Pubitemid 39424080)
12. Matsumori A, Furukawa Y, Hashimoto T, et al. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol. 1997;29:419-423. (Pubitemid 27129164)
13. Hojo Y, Ikeda U, Takahashi M, et al. Increased levels of monocyte-related cytokines in patients with unstable angina. Atherosclerosis. 2002;161:403-408. (Pubitemid 34219194)
14. Nishiyama K, Ogawa H, Yasue H, et al. Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. Jpn Circ J. 1998;62:710-712.
15. Oshima S, Ogawa H, Hokimoto S, et al. Plasma monocyte chemoattractant protein-1 antigen levels and the risk of restenosis after coronary stent implantation. Jpn Circ J. 2001;65:261-264.
16. Hokimoto S, Ogawa H, Saito T, et al. Increased plasma antigen levels of monocyte chemoattractant protein-1 in patients with restenosis after percutaneous transluminal coronary angioplasty. Jpn Circ J. 2000;64:831-834.
17. De Lemos JA, Morrow DA, Sabatine MS, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107:690-695. (Pubitemid 36222595)
18. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [published correction appears in N Engl J Med 2008;18:4]. N Engl J Med. 2004;351:1296-1305.
19. Amann K, Wanner C, Ritz E. Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol. 2006;17:2112-2119. (Pubitemid 44141900)
20. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-2169. (Pubitemid 37337595)
21. Ronco C. Cardiorenal syndromes: definition and classification. Contrib Nephrol. 2010;164:33-38.
22. McCullough PA, Verrill TA. Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med. 2010;122:25-34.
23. Aso Y. Cardiovascular disease in patients with diabetic nephropathy. Curr Mol Med. 2008;8:533-543.
24. Ueda S, Yamagishi S, Kaida Y, et al. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Nephrology (Carlton). 2007;12:582-590. (Pubitemid 350059125)
25. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-992.
26. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res. 2004;95:858-866. (Pubitemid 39435000)
27. Matsui T, Yamagishi S, Takeuchi M, et al. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun. 2009;385:269-272.
28. Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol. 2008;294:F697-F701.
29. Stinghen AE, Gonçalves SM, Martines EG, et al. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract. 2009;111:c117-c26.
30. Lee CD, Folsom AR, Nieto FJ, et al. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and Whitemen and women: atherosclerosis risk in communities study. Am J Epidemiol. 2001;154:758-764. (Pubitemid 32971497)
31. Brown DW, Giles WH, Croft JB. White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol. 2001;54:316-322. (Pubitemid 32162036)
32. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-1482. (Pubitemid 28228207)
33. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published correction appears in N Engl J Med 1997;337:356]. N Engl J Med. 1997;336:973-979. (Pubitemid 27152782)
34. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204. (Pubitemid 30459555)
35. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565. (Pubitemid 35315836)
36. Song C, Hsu K, Yamen E, et al. Serum amyloid A induction of cytokines in monocytes/macrophages and lymphocytes. Atherosclerosis. 2009;207:374-383.
37. Inadera H, Egashira K, Takemoto M, et al. Increase in circulating levels of monocyte chemoattractant protein-1 with aging. J Interferon Cytokine Res. 1999;19:1179-1182. (Pubitemid 29502785)